BeOne Medicines
ONC
#769
Rank
S$41.18 B
Marketcap
S$396.96
Share price
0.20%
Change (1 day)
29.42%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeOne Medicines (ONC)

Earnings in 2026 (TTM): S$0.97 Billion

According to BeOne Medicines's latest financial reports the company's current earnings are S$5.73 Billion. In 2025 the company made an earning of S$0.62 Billion, an increase over its 2024 earnings that were of -S$0.73 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeOne Medicines from 2015 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) S$0.97 B54.24%
2025 S$0.62 B-186.57%
2024 -S$0.73 Billion-52.95%
2023 -S$1.55 Billion-32.52%
2022 -S$2.29 Billion24.39%
2021 -S$1.85 Billion-13.21%
2020 -S$2.13 Billion72.69%
2019 -S$1.23 Billion36.01%
2018 -S$0.91 Billion616.83%
2017 -S$0.13 Billion-15.24%
2016 -S$0.15 Billion107.91%
2015 -S$71.49 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
OPKO Health
OPK
-S$0.21 Billion-121.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
-S$23.24 Million-102.40%๐Ÿ‡บ๐Ÿ‡ธ USA